Safety Concerns Hit Bluebird Sickle Cell Trial, Again

 
• By Alaric DeArment
  
Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
The FDA placed a partial hold on bluebird bio's clinical program for lovo-cel in sickle cell disease • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies